Brief: Ultimovacs Says Cemiplimab To Replace Pembrolizumab In Trial
20/12/2022 08:09
Dec 20 (Reuters) - Ultimovacs ASA ULTI.OL :
* CEMIPLIMAB TO REPLACE PEMBROLIZUMAB IN UV1 PHASE II
LUNGVAC
TRIAL
Source text for Eikon: ID:nObix6nhJa
Further company coverage: ULTI.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant